A genome-wide CRISPR/Cas9 screen identifies calreticulin as a selective repressor of ATF6α.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
29 Jul 2024
Historique:
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: epublish

Résumé

Activating transcription factor 6 (ATF6) is one of three endoplasmic reticulum (ER) transmembrane stress sensors that mediate the unfolded protein response (UPR). Despite its crucial role in long-term ER stress adaptation, regulation of ATF6 alpha (α) signalling remains poorly understood, possibly because its activation involves ER-to-Golgi and nuclear trafficking. Here, we generated an ATF6α/Inositol-requiring kinase 1 (IRE1) dual UPR reporter CHO-K1 cell line and performed an unbiased genome-wide CRISPR/Cas9 mutagenesis screen to systematically profile genetic factors that specifically contribute to ATF6α signalling in the presence and absence of ER stress. The screen identified both anticipated and new candidate genes that regulate ATF6α activation. Among these, calreticulin (CRT), a key ER luminal chaperone, selectively repressed ATF6α signalling: Cells lacking CRT constitutively activated a BiP::sfGFP ATF6α-dependent reporter, had higher BiP levels and an increased rate of trafficking and processing of ATF6α. Purified CRT interacted with the luminal domain of ATF6α

Identifiants

pubmed: 39073063
doi: 10.7554/eLife.96979
pii: 96979
doi:
pii:

Substances chimiques

Activating Transcription Factor 6 0
Calreticulin 0
ATF6 protein, human 0
Protein Serine-Threonine Kinases EC 2.7.11.1

Banques de données

GEO
['GSE254745']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 10.35802/224407
Pays : United Kingdom

Informations de copyright

© 2024, Tung et al.

Déclaration de conflit d'intérêts

JT, LH, GG, HH, AO No competing interests declared, DR Reviewing editor, eLife

Auteurs

Joanne Tung (J)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Lei Huang (L)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Ginto George (G)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Heather P Harding (HP)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.

David Ron (D)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Adriana Ordonez (A)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH